Adaptive Biotechnologies (ADPT) – Analysts’ Weekly Ratings Updates

Adaptive Biotechnologies (NASDAQ: ADPT) recently received a number of ratings updates from brokerages and research firms:

• 8/4/2026 – Adaptive Biotechnologies had its price target raised by Piper Sandler from $20.00 to $27.50. They now have an “overweight” rating on the stock.
• 7/30/2026 – Adaptive Biotechnologies had its price target raised by Guggenheim from $22.00 to $25.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Adaptive Biotechnologies had its price target raised by Morgan Stanley from $20.00 to $22.00. They now have an “equal weight” rating on the stock.
• 7/30/2026 – Adaptive Biotechnologies had its price target raised by TD Cowen from $25.00 to $28.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Adaptive Biotechnologies had its price target raised by BTIG Research from $24.00 to $25.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Adaptive Biotechnologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by TD Cowen.
• 7/9/2026 – Adaptive Biotechnologies had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 6/29/2026 – Adaptive Biotechnologies had its price target raised by Guggenheim from $21.00 to $22.00. They now have a “buy” rating on the stock.
• 6/17/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by BTIG Research. They now have a $22.00 price target on the stock.

Insider Activity at Adaptive Biotechnologies

In other news, insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the transaction, the insider directly owned 221,278 shares in the company, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80. Following the completion of the sale, the insider directly owned 237,688 shares of the company’s stock, valued at $5,336,095.60. The trade was a 17.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,307,086 shares of company stock valued at $27,859,739. 5.70% of the stock is owned by insiders.

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.